LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Inclusion Criteria:

1. Willing to sign the informed consent, and willing to attend follow-up visits.

2. Age ≥ 50

3. Diagnosis of active CNV secondary to neovascular AMD

4. BCVA ETDRS letters between 5 and 63

5. Subjects must have received a minimum of 2 injections within 6 months prior toscreening

6. Demonstrated a meaningful response to anti-VEGF therapy

Exclusion Criteria:

1. CNV or macular edema in the study eye secondary to diseases other than nAMD

2. Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or anycondition preventing visual acuity improvement

3. Acute coronary syndrome, myocardial infarction or coronary artery revascularization,CVA, TIA in the last 6 months

4. Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100mmHg

5. Uncontrolled diabetes defined as HbA1c >7.5%